secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001171843-24-004607
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q2 revenue $41.9M (-5% YoY); net loss $0.1M; launches Integrity Implant System
--------------------------------------------------------------------------------

- Revenue $41.9M, down 5% YoY; OA Pain Mgmt $26.7M (-9%), Joint Preservation $13.5M (+7%).
- Net loss $0.1M ($0.01/sh); adjusted net income $2.5M ($0.17/sh); adjusted EBITDA $6.3M.
- Full market release of Integrity Implant System (HA scaffold) in July; >300 cases by >60 surgeons.
- Guidance: FY2024 revenue $168-$173M (1-4% growth); adjusted EBITDA towards lower end of $25-$30M.
- New $40M share repurchase program; $15M under 10b5-1 plan initiated May 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184324004607/0001171843-24-004607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184324004607/f8k_080824.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer